Silvercrest Asset Management Group LLC lowered its position in Bristol-Myers Squibb Co (NYSE:BMY) by 13.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 219,970 shares of the biopharmaceutical company’s stock after selling 34,473 shares during the period. Silvercrest Asset Management Group LLC’s holdings in Bristol-Myers Squibb were worth $12,855,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the company. Penserra Capital Management LLC increased its stake in Bristol-Myers Squibb by 95.3% in the third quarter. Penserra Capital Management LLC now owns 1,959 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 956 shares during the period. First New York Securities LLC NY acquired a new stake in Bristol-Myers Squibb during the third quarter worth approximately $108,000. State of Alaska Department of Revenue acquired a new stake in Bristol-Myers Squibb during the third quarter worth approximately $109,000. Blume Capital Management Inc. increased its stake in Bristol-Myers Squibb by 2.4% in the third quarter. Blume Capital Management Inc. now owns 2,053 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 48 shares during the period. Finally, Welch Investments LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $119,000. Institutional investors and hedge funds own 69.67% of the company’s stock.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) traded up 0.07% during trading on Friday, hitting $53.48. The company’s stock had a trading volume of 5,224,373 shares. The firm’s 50 day moving average is $55.23 and its 200-day moving average is $54.61. Bristol-Myers Squibb Co has a 1-year low of $46.01 and a 1-year high of $77.12. The company has a market capitalization of $89.46 billion, a P/E ratio of 20.18 and a beta of 1.00. Bristol-Myers Squibb also was the recipient of unusually large options trading on Wednesday. Stock traders acquired 3,241 call options on the stock. This represents an increase of 437% compared to the typical volume of 603 call options.
The firm also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Friday, April 7th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.92%. The ex-dividend date is Wednesday, April 5th. Bristol-Myers Squibb’s payout ratio is presently 58.87%.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://transcriptdaily.com/2017/04/22/silvercrest-asset-management-group-llc-cuts-position-in-bristol-myers-squibb-co-bmy.html.
Several research firms have recently issued reports on BMY. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, January 9th. Evercore ISI reaffirmed a “hold” rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a research note on Sunday, January 8th. Jefferies Group LLC reaffirmed a “buy” rating and set a $69.00 price target on shares of Bristol-Myers Squibb in a research note on Thursday, January 5th. Vetr downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $56.28 target price for the company. in a research note on Monday, March 13th. Finally, Piper Jaffray Companies reissued a “neutral” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, March 8th. Twelve investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $62.48.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 34,000 shares of the company’s stock in a transaction on Friday, April 7th. The stock was sold at an average price of $53.26, for a total transaction of $1,810,840.00. Following the completion of the sale, the director now directly owns 952,571 shares in the company, valued at $50,733,931.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II bought 12,000 shares of the business’s stock in a transaction on Monday, February 27th. The shares were acquired at an average price of $56.77 per share, with a total value of $681,240.00. Following the completion of the purchase, the director now directly owns 12,000 shares of the company’s stock, valued at $681,240. The disclosure for this purchase can be found here. Insiders have sold 190,501 shares of company stock valued at $10,690,203 over the last 90 days. Corporate insiders own 0.24% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
